Skip to main content

Charles River Laboratories guidance

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$335.52−0.72%Close 16 Nov 2026 · Market value $16.05B

In its results release of 4 Nov 2026 (Q3 FY2026), Charles River Laboratories gave 3 forecasts in figures, among them revenue growth of +1.5% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
Revenue growthFY2026+1.5%Revenue growth/(decrease), organic 1.5%
EPS · GAAPFY2026$8.15 to $8.35GAAP EPS estimate $8.15 - $8.35
EPS · AdjustedFY2026$11.35 to $11.55Non-GAAP EPS estimate $11.35 - $11.55

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Revenue growthFY2026+1.5%Unchanged—To come
EPS · GAAPFY2026$8.15 to $8.35Raised once, lowered once—To come
EPS · AdjustedFY2026$11.35 to $11.55Raised 3 times—To come

CRL in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.